Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

The misdiagnosis of interstitial cystitis/bladder pain syndrome in a VA population.

Skove SL, Howard LE, Senechal J, De Hoedt A, Bresee C, Cunningham TJ, Barbour KE, Kim J, Freedland SJ, Anger JT.

Neurourol Urodyn. 2019 Jul 14. doi: 10.1002/nau.24100. [Epub ahead of print]

PMID:
31302944
2.

Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH.

Hanyok BT, Everist MM, Howard LE, De Hoedt AM, Aronson WJ, Cooperberg MR, Kane CJ, Amling CL, Terris MK, Freedland SJ.

Asian J Urol. 2019 Jul;6(3):242-248. doi: 10.1016/j.ajur.2019.01.004. Epub 2019 Jan 18.

3.

Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer.

Moghanaki D, Howard LE, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Apr 29. doi: 10.1038/s41391-019-0146-1. [Epub ahead of print]

PMID:
31036926
4.

Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men.

Vidal AC, Oyekunle T, Howard LE, Shivappa N, De Hoedt A, Figueiredo JC, Taioli E, Fowke JH, Lin PH, Hebert JR, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Apr 12. doi: 10.1038/s41391-019-0143-4. [Epub ahead of print]

PMID:
30980026
5.

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.

Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB.

Prostate Cancer Prostatic Dis. 2019 Feb 25. doi: 10.1038/s41391-019-0134-5. [Epub ahead of print]

PMID:
30804427
6.

Interplay between exercise and BMI; results from an equal access, racially diverse biopsy study.

Michael J, Oyekunle T, Howard L, De Hoedt A, Hoyo C, Grant D, Freedland S.

Cancer Causes Control. 2019 Jan;30(1):13-20. doi: 10.1007/s10552-018-1104-2. Epub 2018 Dec 6.

PMID:
30523509
7.

Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?

Vidal AC, Howard LE, De Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Lechpammer S, Flanders SC, Freedland SJ.

Cancer. 2019 Feb 1;125(3):434-441. doi: 10.1002/cncr.31808. Epub 2018 Nov 14.

PMID:
30427535
8.

Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort.

Michael J, Howard LE, Markt SC, De Hoedt A, Bailey C, Mucci LA, Freedland SJ, Allott EH.

Cancer Prev Res (Phila). 2018 Oct;11(10):621-628. doi: 10.1158/1940-6207.CAPR-18-0057. Epub 2018 Aug 23.

PMID:
30139875
9.

A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts.

Ankerst DP, Straubinger J, Selig K, Guerrios L, De Hoedt A, Hernandez J, Liss MA, Leach RJ, Freedland SJ, Kattan MW, Nam R, Haese A, Montorsi F, Boorjian SA, Cooperberg MR, Poyet C, Vertosick E, Vickers AJ.

Eur Urol. 2018 Aug;74(2):197-203. doi: 10.1016/j.eururo.2018.05.003. Epub 2018 May 16.

PMID:
29778349
10.

Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.

Aminsharifi A, Howard L, Wu Y, De Hoedt A, Bailey C, Freedland SJ, Polascik TJ.

J Urol. 2018 Oct;200(4):758-766. doi: 10.1016/j.juro.2018.05.016. Epub 2018 Jul 6.

PMID:
29758219
11.

Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database.

Vidal AC, Howard LE, de Hoedt A, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Taioli E, Fowke JH, Freedland SJ.

Cancer Causes Control. 2018 Jun;29(6):581-588. doi: 10.1007/s10552-018-1031-2. Epub 2018 Apr 17.

12.

Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Vidal AC, Howard LE, de Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Freedland SJ.

BJU Int. 2018 Jul;122(1):76-82. doi: 10.1111/bju.14193. Epub 2018 Apr 10.

13.

UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression.

Grant DJ, Chen Z, Howard LE, Wiggins E, De Hoedt A, Vidal AC, Carney ST, Squires J, Magyar CE, Huang J, Freedland SJ.

BMC Cancer. 2017 Jul 3;17(1):463. doi: 10.1186/s12885-017-3463-6.

14.

Is Body Mass Index the Best Adiposity Measure for Prostate Cancer Risk? Results From a Veterans Affairs Biopsy Cohort.

Guerrios-Rivera L, Howard L, Frank J, De Hoedt A, Beverly D, Grant DJ, Hoyo C, Freedland SJ.

Urology. 2017 Jul;105:129-135. doi: 10.1016/j.urology.2017.03.042. Epub 2017 Apr 10.

15.

Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.

Howard LE, Moreira DM, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

BJU Int. 2017 Nov;120(5B):E80-E86. doi: 10.1111/bju.13856. Epub 2017 Apr 30.

16.

Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.

Klaassen Z, Howard LE, de Hoedt A, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Cancer. 2017 May 1;123(9):1528-1535. doi: 10.1002/cncr.30505. Epub 2016 Dec 27.

17.

Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?

Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Divers CH, Valderrama A, Freedland SJ.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):380-384. doi: 10.1038/pcan.2016.26. Epub 2016 Jul 5.

18.

Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy.

Freedland SJ, Choeurng V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam LL, Buerki C, Ra S, Robbins B, Trabulsi EJ, Shah NL, Abdollah F, Feng FY, Davicioni E, Dicker AP, Karnes RJ, Den RB.

Eur Urol. 2016 Oct;70(4):588-596. doi: 10.1016/j.eururo.2016.01.008. Epub 2016 Jan 21.

Supplemental Content

Loading ...
Support Center